Josh Schimmer
Stock Analyst at Evercore ISI Group
(4.86)
# 101
Out of 4,496 analysts
89
Total ratings
65%
Success rate
55.41%
Average return
Main Sectors:
36 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LBPH Longboard Pharmaceuticals | Maintains: Outperform | $57 → $80 | $35.95 | +122.53% | 12 | Jul 2, 2024 | |
| BBIO BridgeBio Pharma | Reiterates: Overweight | $70 | $26.19 | +167.28% | 7 | Jul 1, 2024 | |
| INSM Insmed | Maintains: Outperform | $42 → $75 | $75.97 | -1.28% | 3 | Jun 21, 2024 | |
| CABA Cabaletta Bio | Reiterates: Overweight | $50 | $7.09 | +605.22% | 1 | Jun 21, 2024 | |
| ZURA Zura Bio | Reiterates: Overweight | n/a | $3.49 | - | 2 | Jun 17, 2024 | |
| RNA Avidity Biosciences | Maintains: Outperform | $40 → $45 | $45.12 | -0.27% | 3 | Jun 12, 2024 | |
| CRNX Crinetics Pharmaceuticals | Reiterates: Overweight | $65 | $52.66 | +23.43% | 5 | May 14, 2024 | |
| MIRM Mirum Pharmaceuticals | Reiterates: Overweight | $40 | $39.49 | +1.29% | 4 | May 9, 2024 | |
| JANX Janux Therapeutics | Reiterates: Overweight | $100 | $44.68 | +123.81% | 2 | May 9, 2024 | |
| CGON CG Oncology | Reiterates: Overweight | $75 | $35.22 | +112.95% | 3 | May 6, 2024 | |
| XENE Xenon Pharmaceuticals | Reiterates: Overweight | $65 | $42.73 | +52.12% | 2 | Apr 10, 2024 | |
| RCKT Rocket Pharmaceuticals | Maintains: Overweight | $65 | $22.82 | +184.84% | 2 | Feb 27, 2024 | |
| RLYB Rallybio | Maintains: Outperform | $18 → $15 | $1.34 | +1,019.40% | 2 | Dec 21, 2023 | |
| KRYS Krystal Biotech | Maintains: Overweight | $160 → $180 | $203.66 | -11.62% | 3 | Dec 13, 2023 | |
| VTYX Ventyx Biosciences | Downgrades: In-Line | $43 → $5 | $2.55 | +96.08% | 2 | Nov 10, 2023 | |
| FDMT 4D Molecular Therapeutics | Initiates: Overweight | $32 | $14.40 | +122.22% | 1 | Oct 24, 2023 | |
| ERAS Erasca | Maintains: Outperform | $20 → $11 | $2.95 | +272.88% | 2 | Jun 6, 2023 | |
| NBIX Neurocrine Biosciences | Downgrades: In-Line | $140 → $130 | $145.69 | -10.77% | 1 | Nov 14, 2022 | |
| REGN Regeneron Pharmaceuticals | Downgrades: In-Line | $760 | $1,063.60 | -28.54% | 2 | Oct 17, 2022 | |
| SPRO Spero Therapeutics | Upgrades: Outperform | $2 → $8 | $1.40 | +471.43% | 3 | Sep 23, 2022 | |
| ZYME Zymeworks | Initiates: Outperform | $15 | $9.78 | +53.37% | 1 | Mar 15, 2022 | |
| VIRX Viracta Therapeutics | Initiates: Outperform | n/a | $0.55 | - | 1 | Mar 25, 2021 | |
| CGEM Cullinan Oncology | Initiates: Outperform | n/a | $18.29 | - | 1 | Feb 2, 2021 | |
| BYSI BeyondSpring | Initiates: Outperform | n/a | $2.20 | - | 1 | Dec 29, 2020 | |
| RGNX REGENXBIO | Upgrades: Outperform | n/a | $12.58 | - | 3 | Feb 25, 2019 | |
| MDGL Madrigal Pharmaceuticals | Upgrades: Outperform | n/a | $287.24 | - | 3 | Nov 16, 2018 | |
| BLUE bluebird bio | Upgrades: Outperform | n/a | $1.05 | - | 3 | Jun 19, 2018 | |
| INCY Incyte | Upgrades: Outperform | n/a | $65.87 | - | 2 | Jun 11, 2018 | |
| IONS Ionis Pharmaceuticals | Downgrades: In-Line | n/a | $47.82 | - | 2 | May 8, 2018 | |
| VYGR Voyager Therapeutics | Downgrades: In-Line | n/a | $8.37 | - | 2 | Mar 12, 2018 | |
| DNLI Denali Therapeutics | Downgrades: In-Line | n/a | $21.46 | - | 2 | Mar 12, 2018 | |
| QURE uniQure | Initiates: Outperform | n/a | $7.74 | - | 1 | Nov 7, 2017 | |
| BOLD Boundless Bio | Downgrades: In-Line | n/a | $3.56 | - | 2 | Oct 16, 2017 | |
| TBPH Theravance Biopharma | Initiates: Outperform | n/a | $9.57 | - | 1 | Aug 17, 2017 | |
| BMRN BioMarin Pharmaceutical | Initiates: Outperform | n/a | $84.09 | - | 1 | Aug 17, 2017 | |
| ABBV AbbVie | Initiates: Outperform | n/a | $172.32 | - | 1 | Aug 17, 2017 |
Longboard Pharmaceuticals
Jul 2, 2024
Maintains: Outperform
Price Target: $57 → $80
Current: $35.95
Upside: +122.53%
BridgeBio Pharma
Jul 1, 2024
Reiterates: Overweight
Price Target: $70
Current: $26.19
Upside: +167.28%
Insmed
Jun 21, 2024
Maintains: Outperform
Price Target: $42 → $75
Current: $75.97
Upside: -1.28%
Cabaletta Bio
Jun 21, 2024
Reiterates: Overweight
Price Target: $50
Current: $7.09
Upside: +605.22%
Zura Bio
Jun 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $3.49
Upside: -
Avidity Biosciences
Jun 12, 2024
Maintains: Outperform
Price Target: $40 → $45
Current: $45.12
Upside: -0.27%
Crinetics Pharmaceuticals
May 14, 2024
Reiterates: Overweight
Price Target: $65
Current: $52.66
Upside: +23.43%
Mirum Pharmaceuticals
May 9, 2024
Reiterates: Overweight
Price Target: $40
Current: $39.49
Upside: +1.29%
Janux Therapeutics
May 9, 2024
Reiterates: Overweight
Price Target: $100
Current: $44.68
Upside: +123.81%
CG Oncology
May 6, 2024
Reiterates: Overweight
Price Target: $75
Current: $35.22
Upside: +112.95%
Xenon Pharmaceuticals
Apr 10, 2024
Reiterates: Overweight
Price Target: $65
Current: $42.73
Upside: +52.12%
Rocket Pharmaceuticals
Feb 27, 2024
Maintains: Overweight
Price Target: $65
Current: $22.82
Upside: +184.84%
Rallybio
Dec 21, 2023
Maintains: Outperform
Price Target: $18 → $15
Current: $1.34
Upside: +1,019.40%
Krystal Biotech
Dec 13, 2023
Maintains: Overweight
Price Target: $160 → $180
Current: $203.66
Upside: -11.62%
Ventyx Biosciences
Nov 10, 2023
Downgrades: In-Line
Price Target: $43 → $5
Current: $2.55
Upside: +96.08%
4D Molecular Therapeutics
Oct 24, 2023
Initiates: Overweight
Price Target: $32
Current: $14.40
Upside: +122.22%
Erasca
Jun 6, 2023
Maintains: Outperform
Price Target: $20 → $11
Current: $2.95
Upside: +272.88%
Neurocrine Biosciences
Nov 14, 2022
Downgrades: In-Line
Price Target: $140 → $130
Current: $145.69
Upside: -10.77%
Regeneron Pharmaceuticals
Oct 17, 2022
Downgrades: In-Line
Price Target: $760
Current: $1,063.60
Upside: -28.54%
Spero Therapeutics
Sep 23, 2022
Upgrades: Outperform
Price Target: $2 → $8
Current: $1.40
Upside: +471.43%
Zymeworks
Mar 15, 2022
Initiates: Outperform
Price Target: $15
Current: $9.78
Upside: +53.37%
Viracta Therapeutics
Mar 25, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.55
Upside: -
Cullinan Oncology
Feb 2, 2021
Initiates: Outperform
Price Target: n/a
Current: $18.29
Upside: -
BeyondSpring
Dec 29, 2020
Initiates: Outperform
Price Target: n/a
Current: $2.20
Upside: -
REGENXBIO
Feb 25, 2019
Upgrades: Outperform
Price Target: n/a
Current: $12.58
Upside: -
Madrigal Pharmaceuticals
Nov 16, 2018
Upgrades: Outperform
Price Target: n/a
Current: $287.24
Upside: -
bluebird bio
Jun 19, 2018
Upgrades: Outperform
Price Target: n/a
Current: $1.05
Upside: -
Incyte
Jun 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $65.87
Upside: -
Ionis Pharmaceuticals
May 8, 2018
Downgrades: In-Line
Price Target: n/a
Current: $47.82
Upside: -
Voyager Therapeutics
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $8.37
Upside: -
Denali Therapeutics
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $21.46
Upside: -
uniQure
Nov 7, 2017
Initiates: Outperform
Price Target: n/a
Current: $7.74
Upside: -
Boundless Bio
Oct 16, 2017
Downgrades: In-Line
Price Target: n/a
Current: $3.56
Upside: -
Theravance Biopharma
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $9.57
Upside: -
BioMarin Pharmaceutical
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $84.09
Upside: -
AbbVie
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $172.32
Upside: -